Thursday, December 04, 2025 6:05:14 PM
Throughout 2025, virtually all share dilution has occurred at an average price of $0.25–$0.30.
With authorized shares nearly exhausted, the company is now seeking shareholder approval to increase the authorized share count by an additional 900 million.
And there's no transparency to the purpose of 900 million A/S.
This raises a fair question:
If management possesses strong capital-planning foresight, why was sufficient capital not raised throughout 2021 when the stock traded around $1.50?
Raising funds at that level—approximately 5–6× the current dilution price—could have generated the same (or greater) cash proceeds while issuing far fewer shares.
Such a strategy might have preserved significant authorized share capacity within the existing 1.7 billion limit and reduced the ongoing dilutive pressure we’re experiencing today.
Instead, we’ve had relentless dilution at pennies, zero meaningful capital raised when the stock had real value, and now we’re stuck with a share price under a quarter—while being told “approval is imminent.” (for how many years now?)
Serious question: had management been remotely strategic or transparent four years ago, would we even be in this position today?
I am holding my vote until the last week of ASM, waiting for any updates or factual information to make a final call.
NO COMPENSATION to managements.
"Show me the money first before you ask for it!"
With authorized shares nearly exhausted, the company is now seeking shareholder approval to increase the authorized share count by an additional 900 million.
And there's no transparency to the purpose of 900 million A/S.
This raises a fair question:
If management possesses strong capital-planning foresight, why was sufficient capital not raised throughout 2021 when the stock traded around $1.50?
Raising funds at that level—approximately 5–6× the current dilution price—could have generated the same (or greater) cash proceeds while issuing far fewer shares.
Such a strategy might have preserved significant authorized share capacity within the existing 1.7 billion limit and reduced the ongoing dilutive pressure we’re experiencing today.
Instead, we’ve had relentless dilution at pennies, zero meaningful capital raised when the stock had real value, and now we’re stuck with a share price under a quarter—while being told “approval is imminent.” (for how many years now?)
Serious question: had management been remotely strategic or transparent four years ago, would we even be in this position today?
I am holding my vote until the last week of ASM, waiting for any updates or factual information to make a final call.
NO COMPENSATION to managements.
"Show me the money first before you ask for it!"
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
